Table 2.

Analysis of the eGFR slopes.

Cohort	Group	N	Mean	Between-group difference, mL/min/1.73 m2/year (95% CI)	P	P for interaction
Entire cohort	Placebo	203	− 0.46	0.31 (− 0.11 to 0.73)	0.762	NA
	Febuxostat	192	− 0.15
Entire cohort	Proteinuria-negative	218	0.20	− 1.15 (− 1.56 to − 0.74)	< 0.001	NA
	Proteinuria-positive	177	− 0.94
Entire cohort	s-Cre < median	192	0.19	− 0.98 (− 1.39 to − 0.57)	< 0.001	NA
	s-Cre ≥ median	203	− 0.79
Proteinuria						0.019
Negative	Placebo	110	− 0.15	0.72 (− 0.20 to 1.24)	0.007
	Febuxostat	108	0.60
Positive	Placebo	93	− 0.82	− 0.25 (− 0.89 to 0.39)	0.439
	Febuxostat	84	− 1.08
s-Cre						0.283
< Median	Placebo	98	− 0.07	0.53 (− 0.02 to 1.09)	0.061
	Febuxostat	94	0.47
≥ Median	Placebo	105	− 0.83	0.09 (− 0.52 to 0.69)	0.780
	Febuxostat	98	− 0.74
Cross-classified cohort						0.064
Proteinuria-negative and s-Cre < median	Placebo	52	0.45	0.64 (− 0.09 to 1.38)	0.086
	Febuxostat	55	1.09
Proteinuria-negative and s-Cre ≥ median	Placebo	58	− 0.69	0.72 (0.03 to 1.41)	0.040
	Febuxostat	53	0.03
Proteinuria-positive and s-Cre < median	Placebo	46	− 0.65	− 0.24 (− 0.54 to 1.01)	0.543
	Febuxostat	39	− 0.41
Proteinuria-positive and s-Cre ≥ median	Placebo	47	− 0.99	− 0.65 (− 0.33 to 1.64)	0.191
	Febuxostat	45	− 1.65

CI confidence interval, eGFR estimated glomerular filtration rate, s-Cre serum creatinine.